Creo Medical Group PLC (LON:CRO) jumped higher on Thursday after the medical device company announced the successful first use of its Speedboat endoscopic advanced energy device in seven upper gastrointestinal (GI) tract patients in South Africa.
Speedboat is the first device developed for use with the Welsh company's CROMA generator, which allows doctors to carry out surgical procedures without the need to puncture the skin.
READ: Two huge licensing deals help Oxford BioMedica swing to a first-half profit
CROMA is an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave technology for controlled coagulation.
The AIM-listed group said Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths.
Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures.
Craig Gulliford, Creo's chief executive officer, said: "This is a double first for Creo. The use of our lead product, Speedboat, in upper GI procedures and in a clinical setting outside of the UK is a key step in the commercialisation of our technology.”
In early afternoon trading, Creo Medical shares were up 13% at 189.5p.